# creating ADDED VALUE

Rice Powell - CEO

00

0

0



0

00

J. P. Morgan Healthcare Conference, San Francisco, January 7-8, 2019 **Safe harbor statement**: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20-F under the heading "Forward-Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).


Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.


If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.





#### Q3 2018: Growth continued








Segment revenue FY 2017, according to IFRS in EUR bn, number of patients and clinics as of YE 2017, yoy change

© January 2019 5

#### Organic growth drivers

Patient growth driven by

- age, lifestyle and higher life expectancy
- increasing wealth and access to medical treatments






1 Internal estimates as of Dec. 31, 2017


© January 2019 6







#### -Care Coordination strategy



## Expertise in value based care programs

- Intensive learning curve with US government
- 40,000 ESCO patients providing significant insight in health care treatments also outside dialysis
- Own Medicare Advantage Plan
- Sub-capitated agreements
- Dedicated Care Navigation Unit




#### -Home Dialysis Segment: Opportunity

Significant growth opportunity in home modalities


#### Home dialysis treatment by modality in 2017

(in % of ESRD cases)



## FME home dialysis patients in the U.S.

(in % of FME patients in the U.S.)





#### Q3 2018: Update

- Improved sequential quarterly growth in dialysis business in North America
- Business acceleration muted due to:
  - Lower revenue from commercial payors and delayed de novos in North America
  - Lower than expected contribution from vascular access business in Care Coordination
  - Difficult environment in emerging economies
- Care Coordination margin improvement
- Strong commitment to home U.S. penetration rate of 12.4% achieved
- NxStage update



#### -Q3 2018: Solid comparable growth

	<b>Q3 2018</b> € million	Q3 2017 € million	Growth in %	Growth in %cc
Revenue	4,058	4,336	(6)	(6)
Revenue on a comparable basis	4,058	3,966	2	3
EBIT	527	609	(13)	(20)
EBIT on a comparable basis	615	589	5	4
Net income	285	309	(8)	(17)
Net income on a comparable basis	364	304	20	19
Net income adjusted	310	314	(1)	(2)

- Revenue impacted by divestiture of Sound, IFRS 15 implementation and lower organic growth in North America
- Net income growth on a comparable basis on a high level



#### -Q3 2018: Organic growth

North America	€ million	
Revenue	2,843	(11)%cc
Organic growth		+2%
Asia-Pacific	€ million	
Revenue	421	+4%cc
Organic growth		+5%

EMEA	€ million	
Revenue	620	+1%cc
Organic growth		0%
Latin America	€ million	
Revenue	171	+27%cc
Organic growth		+26%

- North America growth impacted by lower Care Coordination revenue and lower growth in dialysis business
- Stable development in EMEA






### -Q3 2018 Services: Organic growth continued

Revenue	<b>Q3 2018</b> € million	<b>Q3 2017</b> € million	Growth in %	Growth in %cc	Organic growth in %	Same market growth in %
Total	3,258	3,532	(8)	(8)	4	3
North America	2,628	2,904	(10)	(11)	3	3
of which Care Coordination	300	705	(57)	(61)	(26)	-
EMEA	314	311	1	4	3	3
Asia-Pacific	194	194	1	1	5	6
of which Care Coordination	54	52	4	7	5	_
Latin America	122	123	(1)	34	34	1

- North America with improved sequential volume growth but impacted by lower revenue from commercial payors
- EMEA and Latin America growth with headwinds from currency fluctuation





Como

80%

10%

6%

4%

### -Q3 2018 Products: Stable contribution post strong H1

	<b>Q3 2018</b> € million	<b>Q3 2017</b> € million	Growth in %	Growth in %cc
Total Health Care Products	800	804	0	1
Dialysis Products	782	785	0	2
North America	215	211	2	1
EMEA	288	302	(5)	(2)
Asia-Pacific	227	217	4	6
Latin America	49	52	(5)	9
Non-Dialysis Products	18	19	(7)	(7)

- EMEA: Lower sales of dialyzers, higher sales of machines, acute products and renal pharmaceuticals
- Asia-Pacific: Growth in sales of chronic and acute HD products
- North America: Higher sales of renal drugs, peritoneal products, lower sales of chronic HD products





#### Outlook

	Targets 2018 <sup>1</sup>	<b>2017 base</b> (in € million)
Revenue growth on a comparable basis	2 to 3%	16,739
Net income growth on a comparable basis	11 to 12%	1,242
Net income growth on an adjusted basis	2 to 3%	1,162
	Indicative guid	lance 2019 <sup>2</sup>
Revenue growth on a comparable basis	Solid gr	owth
Net income on a comparable basis	Stable	level
<sup>1</sup> Based on constant currencies, excl. effects from NxStage For a detail	ed reconciliation of 9M 2017 & 9M 2018 fi <sup>2</sup> For details on "comparable l	

Reset 2020 targets planned to be released on February 20, 2019.



# creating ADDED VALUE

Rice Powell - CEO

00

0

0



0

00

J. P. Morgan Healthcare Conference, San Francisco, January 7-8, 2019


# Backup

Ô



#### Basis for revenue growth 2019

Revenue (€m)



"Comparable" is on a constant currency basis and reflects an adjustment for those effects that are as per the company's view not related to the company's operating business performance such as, for example, the effects of IFRS 16, sizeable portfolio changes like the divestiture of Sound Inpatient Physicians Holdings or the pending acquisition of NxStage Medical Inc. or other effects of one-time nature like FCPA-related charges or the cost of the 2018 U.S. ballot initiatives. For the preliminary indicative 2019 guidance the "comparable" 2018 basis translates roughly at current currencies for revenue in a range of 15,850 - 16,050 EUR million and for net income in a range of 1,350 - 1,365 EUR million. This is subject to fluctuations in the currency rates in the fourth quarter of 2018.




#### Basis for net income growth 2019 Net income (€m) 2018 target: 11-12% cc 1,379 -137-1,391 149 33-30 1,350 -1,346 -1,365 1,361 1,280 38 1,242 2017 Sound 2017 on a **Business** 2018 cc FX 2018 Sound 2018 comparable H1 2018 comparable reported H2 2017 growth cc on a current on a basis for comparable comparable basis basis 2019 basis guidance

"Comparable" is on a constant currency basis and reflects an adjustment for those effects that are as per the company's view not related to the company's operating business performance such as, for example, the effects of IFRS 16, sizeable portfolio changes like the divestiture of Sound Inpatient Physicians Holdings or the pending acquisition of NxStage Medical Inc. or other effects of one-time nature like FCPA-related charges or the cost of the 2018 U.S. ballot initiatives. For the preliminary indicative 2019 guidance the "comparable" 2018 basis translates roughly at current currencies for revenue in a range of 15,850 – 16,050 EUR million and for net income in a range of 1,350 – 1,365 EUR million. This is subject to fluctuations in the currency rates in the fourth quarter of 2018.



#### Reasons for target adjustments

Adjustment of **Revenue growth** on a comparable basis driven by:



Adjustment of **Net income growth** 

Size of bubble indicative only to illustrate relative impact on the target adjustments.




#### Basis for targets 2018

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures.

€ million	2017	Targets 2018
Revenue	17,784	
Effect from IFRS 15 implementation	(486)	
Sound H2 2017 <sup>1</sup>	(559)	
Revenue on a comparable basis	16,739	Growth: 2-3%cc
Net income <sup>2</sup>	1,280	
Sound H2 2017 <sup>1</sup>	(38)	
Net income <sup>2</sup> on a comparable basis	1,242	Growth: 11-12%cc
VA agreement <sup>3</sup>	(51)	
Natural Disaster Costs <sup>4</sup>	11	
FCPA related charge	200	
U.S. tax reform <sup>5</sup> (excl. Sound H2 2017 <sup>1</sup> )	(240)	
Net income <sup>2</sup> adjusted	1,162	Growth: 2-3%cc


<sup>1</sup> Contribution of Sound Physicians | <sup>2</sup> Attributable to shareholders of FME | <sup>3</sup> Agreement with the United States Departments of Veterans Affairs and Justice | <sup>4</sup> Three hurricanes and an earthquake | <sup>5</sup> Remeasurement of deferred tax balances as a result of U.S. tax reform







# 9M 2018: Growth trend - organic and volume (%) -





	<b>Q3 2018</b> € million	Q3 2017 € million	Growth in %	Growth in %cc
Revenue	4,058	4,336	(6)	(6)
Revenue on a comparable basis	4,058	3,966	2	3
Revenue adjusted	4,058	3,969	2	3
EBIT	527	609	(13)	(20)
EBIT margin in %	13.0	14.0	(1.0)рр	(2.0)pp
EBIT on a comparable basis	615	589	5	4
EBIT adjusted	615	604	2	1
EBIT adjusted margin in %	15.1	15.2	(0.1)pp	(0.2)pp
Net interest expense	74	86	(14)	(14)
Income before taxes	453	523	(13)	(21)
Income tax expense	104	152	(32)	(38)
Tax rate in %	22.9	29.0	(6.1)pp	(6.1)pp
Non-controlling interest	64	62	4	3
Net income	285	309	(8)	(17)
Net income on a comparable basis	364	304	20	19
Net income adjusted	310	314	(1)	(2)





<sup>1</sup> For a detailed reconciliation please refer to chart 29 and 30

© | January 2019 26

## Q3 2018: Reconciliation adjustments (1/2)

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

€ million	Q3 2017	Q3 2018	Growth in %	Growth in %cc
Revenue	4,336	4,058	(6)	(6)
Effect from IFRS 15 implementation	(117)			
Sound Q3 2017 <sup>1</sup>	(253)			
Revenue on a comparable basis	3,966	4,058	2	3
VA Agreement <sup>2</sup>	3			
Revenue adjusted	3,969	4,058	2	3
Operating income (EBIT)	609	527	(13)	(20)
(Gain) loss related to divestitures of Care Coordination activities		(10)		
Sound Q3 2017 <sup>1</sup>	(20)			
2018 FCPA related charge		75		
U.S. Ballot Initiatives <sup>3</sup>		23		
EBIT on a comparable basis	589	615	5	4
VA Agreement <sup>2</sup>	3			
Natural Disaster Costs <sup>4</sup>	12			
EBIT adjusted	604	615	2	1

<sup>1</sup> Sound Q3 2017: contribution of Sound Physicians | <sup>2</sup> VA Agreement with the United States Departments of Veterans Affairs and Justice | <sup>3</sup> U.S. Ballot Initiatives: contributions to the ballot opposition initiatives in the U.S. | <sup>4</sup> Natural Disaster Costs: three hurricanes and an earthquake | <sup>5</sup> Attributable to shareholders | <sup>6</sup> U.S. Tax Reform: impacts from U.S. tax reform



### Q3 2018: Reconciliation adjustments (2/2)

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures


€ million	Q3 2017	Q3 2018	Growth in %	Growth in %cc
Net income <sup>5</sup>	309	285	(8)	(17)
(Gain) loss related to divestitures of Care Coordination activities		(17)		
Sound Q3 2017 <sup>1</sup>	(5)			
2018 FCPA related charge		75		
U.S. Ballot Initiatives <sup>3</sup>		21		
Net income <sup>₅</sup> on a comparable basis	304	364	20	19
VA Agreement <sup>2</sup>	2			
Natural Disaster Costs <sup>4</sup>	8			
U.S. tax reform <sup>6</sup>		(54)		
Net income <sup>5</sup> adjusted	314	310	(1)	(2)

<sup>1</sup> Sound Q3 2017: contribution of Sound Physicians | <sup>2</sup> VA Agreement with the United States Departments of Veterans Affairs and Justice | <sup>3</sup> U.S. Ballot Initiatives: contributions to the ballot opposition initiatives in the U.S. | <sup>4</sup> Natural Disaster Costs: three hurricanes and an earthquake | <sup>5</sup> Attributable to shareholders | <sup>6</sup> U.S. Tax Reform: impacts from U.S. tax reform




#### -Q3 2018: Revenue growth

Revenue on a **comparable basis**, € million - target: 2-3%cc growth









#### Q3 2018: Regional margin profile



#### Improved dialysis business margin of 19.2%


- Negative: U.S. Ballot Initiatives, lower growth of patients with commercial contracts, lower contribution from acute services and delayed certification of de novos
- Positive: Lower personnel expense, income attributable to a consent agreement on certain pharmaceuticals
- U.S. revenue per treatment increased to \$356 (Q2 2018: \$354);
   U.S. cost per treatment increased to \$290 (Q2 2018: \$289)
- Care Coordination margin improved
  - Positive: Improved profitability due to divestiture of Sound and the shift of calcimimetics to the dialysis business
  - Negative: Higher prior year contribution due to initial recognition for the new 2017 ESCOs and lower contribution from vascular business



1 Excl. Corporate

© January 2019 31

#### -Q3 2018: Regional margin profile



	<b>9M 2018</b> € million	9M 2017 € million	Growth in %	Growth in %cc
Revenue	12,247	13,355	(8)	(2)
Revenue on a comparable basis	12,247	12,715	(4)	3
Revenue adjusted	12,247	12,619	(3)	4
EBIT	2,425	1,843	32	39
EBIT margin in %	19.8	13.8	6.0pp	5.8pp
EBIT on a comparable basis	1,698	1,823	(7)	(2)
EBIT adjusted	1,698	1,747	(3)	2
EBIT adjusted margin in %	13.9	13.8	0.1pp	(0.2)pp
Net interest expense	239	274	(13)	(8)
Income before taxes	2,186	1,569	39	47
Income tax expense	453	484	(6)	(1)
Tax rate in %	20.7	30.8	(10.1)pp	(10.1)pp
Non-controlling interest	176	199	(12)	(5)
Net income	1,557	886	76	86
Net income on a comparable basis	969	881	10	16
Net income adjusted	832	837	(1)	4





<sup>1</sup> For a detailed reconciliation please refer to chart 36 and 37

© | January 2019 33

## 9M 2018: Reconciliation adjustments (1/2)

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

€ million	9M 2017	9M 2018	Growth in %	Growth in %cc
Revenue	13,355	12,247	(8)	(2)
Effect from IFRS 15 implementation	(387)			
Sound Q3 2017 <sup>1</sup>	(253)			
Revenue on a comparable basis	12,715	12,247	(4)	3
VA Agreement	(96)			
Revenue adjusted	12,619	12,247	(3)	4
Operating income (EBIT)	1,843	2,425	32	39
(Gain) loss related to divestitures of Care Coordination activities		(830)		
Sound Q3 2017 <sup>1</sup>	(20)			
2018 FCPA related charge		75		
U.S. Ballot Initiatives <sup>3</sup>		28		
EBIT on a comparable basis	1,823	1,698	(7)	(2)
VA Agreement <sup>2</sup>	(88)			
Natural Disaster Costs <sup>4</sup>	12			
EBIT adjusted	1,747	1,698	(3)	2

<sup>1</sup> Sound Q3 2017: contribution of Sound Physicians | <sup>2</sup> VA Agreement with the United States Departments of Veterans Affairs and Justice | <sup>3</sup> U.S. Ballot Initiatives: contributions to the ballot opposition initiatives in the U.S. | <sup>4</sup> Natural Disaster Costs: three hurricanes and an earthquake | <sup>5</sup> Attributable to shareholders | <sup>6</sup> U.S. Tax Reform: impacts from U.S. tax reform



## 9M 2018: Reconciliation adjustments (2/2)

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures

€ million	9M 2017	9M 2018	Growth in %	Growth in %cc
Net income <sup>5</sup>	886	1,557	76	86
(Gain) loss related to divestitures of Care Coordination activities		(690)		
Sound Q3 2017 <sup>1</sup>	(5)			
2018 FCPA related charge		75		
U.S. Ballot Initiatives <sup>3</sup>		27		
Net income on a comparable basis	881	969	10	16
VA Agreement <sup>2</sup>	(52)			
Natural Disaster Costs <sup>4</sup>	8			
U.S. tax reform <sup>6</sup>		(137)		
Net income adjusted	837	832	(1)	4

<sup>1</sup>Sound Q3 2017: contribution of Sound Physicians | <sup>2</sup> VA Agreement with the United States Departments of Veterans Affairs and Justice | <sup>3</sup> U.S. Ballot Initiatives: contributions to the ballot initiatives in the U.S. | <sup>4</sup> Natural Disaster Costs: three hurricanes and an earthquake | <sup>5</sup> Attributable to shareholders | <sup>6</sup> U.S. Tax Reform: impacts from U.S. tax reform




#### 9M 2018: Revenue reconciliation Revenue on a comparable basis, € million - target: 2-3%cc growth 3%cc 13,355 253 13,107 387 488 12,715 860 96 12,247 IFRS 15 9m 2017 9m 2017 VA 9m 2018 cc 9m 2018 Sound Business FX 9m 2018 reported Agreement growth cc on a reported on a comparable comparable comparable basis basis basis



# 9M 2018: Net income growth

Net income on a comparable basis, € million - target: 11-12%cc growth





### 9M 2018 Services

Revenue	<b>9M 2018</b> € million	<b>9M 2017</b> € million	Growth in %	Growth in %cc	Organic growth in %	Same market growth in %
Total	9,852	10,950	(10)	(3)	3	3
North America	7,979	9,086	(12)	(6)	2	3
of which Care Coordination	1,345	2,094	(36)	(31)	(22)	_
EMEA	943	925	2	5	3	3
Asia-Pacific	569	553	3	9	6	6
of which Care Coordination	148	111	33	42	11	-
Latin America	361	386	(7)	21	19	1



1	North America	81%
2	EMEA	<b>9</b> %
3	Asia-Pacific	6%
4	Latin America	4%



### 9M 2018 Products

	<b>9M 2018</b> € million	<b>9M 2017</b> € million	Growth in %	Growth in %cc
Total Health Care Products	2,395	2,405	0	5
Dialysis Products	2,339	2,345	0	5
North America	610	629	(3)	4
EMEA	909	903	1	3
Asia-Pacific	666	653	2	7
Latin America	144	149	(3)	12
Non-Dialysis Products	56	60	(7)	(7)



1	EMEA	41%	
2	Asia-Pacific	28%	
3	North America	25%	
4	Latin America	6%	



#### Debt and EBITDA

#### Reconciliation of non-IFRS financial measures to the most comparable IFRS measure

#### € million

Debt	FY 2016	FY 2017	9M 2018
Short term debt	572	760	1,210
+ Short term debt from related parties		9	23
+ Current portion of long-term debt and capital lease obligations	724	884	1,096
<ul> <li>+ Long-term debt and capital lease obligations less current portion</li> </ul>	6,833	5,795	5,041
Total debt	8,132	7,448	7,370
Cash and cash equivalents	709	978	1,754
Total net debt	7,423	6,470	5,616
EBITDA	FY 2016 <sup>1</sup>	FY 2017 <sup>1</sup>	9M 2018 <sup>1</sup>
Last twelve month operating income (EBIT)	2,398	2,372	2,021
+ Last twelve month depreciation and amortization	710	731	701
+ Non-cash charges	65	51	42
EBITDA (annualized)	3,173	3,154	2,764
Net leverage ratio (Net debt/EBITDA)	2.3	2.1	2.0

1 EBITDA: including acquisitions & divestitures with a purchase price above €50m and in 2018 excluding (gain) loss related to divestitures of Care Coordination activities



### Cash Flow and Capital Expenditures


Reconciliation of non-IFRS financial measures to the most comparable IFRS measure

#### € million

Cash Flow	Q3 2017	Q3 2018	9M 2017	9M 2018
Acquisitions, investments and net purchases of intangible assets	(77)	(462)	(428)	(808)
- Proceeds from divestitures	21	149	31	1,811
= Acquisitions and investments, net of divestitures	(56)	(313)	(397)	1,003

Capital expenditures, net	Q3 2017	Q3 2018	9M 2017	9M 2018
Purchase of property, plant and equipment	(228)	(266)	(632)	(732)
- Proceeds from sale of property, plant & equipment	2	9	18	30
= Capital expenditure, net	(226)	(257)	(614)	(702)







© January 2019 42

## -Q3 2018: Quality outcomes remain on high level<sup>1</sup>

	North A	America	EN	1EA	Latin A	merica	Asia-P	acific
% of patients	Q3 2018	Q3 2017	Q3 2018	Q3 2017	Q3 2018	Q3 2017	Q3 2018	Q3 2017
Kt/V > 1.2	97	98	94	95	91	92	96	96
Hemoglobin = 10–12 g/dl	72	73	82	82	53	51	58	58
Calcium = $8.4-10.2$ mg/dl	85	85	80	79	75	78	73	75
Albumin ≥ 3.5 g/dl	80	78	90	88	91	91	89	88
Phosphate $\leq$ 5.5 mg/dl	61	62	79	78	76	76	67	70
Patients without catheter (after 90 days)	83	84	79	80	80	81	87	88
in days								
Days in hospital per patient year	10.0	9.9	7.4	7.8	4.2	4.0	3.5	3.8

1 Definitions cf. Annual Report 2017, Section "Non-Financial Group Report"




### -9M 2018: Patients, treatments, clinics

	Patients as of Sep. 30, 2018	Treatments as of Sep. 30, 2018	Clinics as of Sep. 30, 2018
North America	201,220	22,867,793	2,486
Growth in %	3	3	5
EMEA	64,539	7,250,376	769
Growth in %	4	4	5
Asia-Pacific	31,152	3,239,862	390
Growth in %	3	2	0
Latin America	32,174	3,764,542	227
Growth in %	5	4	(1)
Total	329,085	37,122,573	3,872
Growth in %	4	3	4



## Our portfolio of Care Coordination businesses

Mid-term revenue and growth profile - 2020e



Size of circle indicates absolute revenue contribution in 2020e. Positioning of bubble illustrative.



-U.S. dialysis days per	quarte	r ——			
	Q1	Q2	Q3	Q4	Full year
2018	77	78	78	80	313
2017	77	78	79	79	313
2016	78	78	79	79	314
2015	76	78	79	79	312



#### Exchange rates

-		9M 2017	FY 2017	9M 2018
€:\$	Period end	1.181	1.199	1.158
	Average	1.114	1.130	1.194
€:CNY	Period end	7.853	7.804	7.966
	Average	7.577	7.629	7.779
€:RUB	Period end	68.252	69.392	76.142
	Average	64.999	65.938	73.395
€:ARS	Period end	20.500	22.639	47.423
	Average	18.135	18.754	29.845
€:BRL	Period end	3.764	3.973	4.654
	Average	3.535	3.605	4.297



### Definitions

СС	Constant currency
HD	Hemodialysis
PD	Peritoneal dialysis
Net income	Net income attributable to shareholders of FME
Sound H2 2017	Contribution of Sound Physicians on the profit and loss statement in the second half year 2017
U.S. Tax Reform	U.S. Tax Reform: impacts from U.S. tax reform
VA Agreement	Agreement with the United States Departments of Veterans Affairs and Justice



#### -Financial calendar 2019<sup>1</sup>

Feb 20	Report on 4 <sup>th</sup> quarter 2018
May 2	Report on 1 <sup>st</sup> quarter 2019
May 16	Annual General Meeting, Frankfurt

Jan 21-22	UniCredit & Kepler Cheuvreux German Corporate Conference, Frankfurt
March 6	Credit Suisse Healthcare Conference, London
March 12-13	Barclays Global Healthcare Conference, Miami

<sup>1</sup> Please note that dates and/or participation might be subject to change



#### Contacts

**FME Investor Relations** Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany

WKN: ISIN:

Ticker: FME or FMS (NYSE) 578 580 DE00057858002

Dr. Dominik Heger Head of Investor Relations and **Corporate Communications** Tel.: +49-(0) 6172-609-2601 Email: dominik.heger@fmc-ag.com

**Robert Adolph** Senior Director Investor Relations Tel.: +49-(0) 6172-609-2477 Email: robert.adolph@fmc-ag.com

#### Juliane Beckmann

Senior Manager Investor Relations Tel.: +49-(0) 6172-609-5216 Email: juliane.beckmann@fmc-ag.com

Philipp Gebhardt Senior Manager Investor Relations +1-781-699-2142 Tel.:







**Constant currency:** Changes in revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items include the impact of changes in foreign currency exchange rates. We use the non-IFRS financial measure "at constant exchange rates" or constant currency in our filings to show changes in our revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items without giving effect to period-to-period currency fluctuations. Under IFRS, amounts received in local (non-Euro) currency are translated into Euros at the average exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period using the prior period exchange rates versus the prior period. This resulting percentage is a non-IFRS measure referring to a change as a percentage "at constant currency."

We believe that the non-IFRS financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on a company's revenue, operating income and other items from period to period. However, we also believe that the usefulness of data on constant currency period-over-period changes is subject to limitations, particularly if the currency effects that are eliminated constitute a significant element of our revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items and significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency into Euros. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-IFRS revenue, operating income, net income attributable to shareholders of this report to follow a similar approach by considering data on constant currency period-over, period-over-period changes of this report to follow a similar approach by considering data on constant currency period-over, period-over-period changes of FMC AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from IFRS measures next to the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived fr

